These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37167718)

  • 81. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
    Yu B; Zheng L; Tang H; Wang W; Lin Y
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.
    Schueler J; Tschuch C; Klingner K; Bug D; Peille AL; de Koning L; Oswald E; Klett H; Sommergruber W
    Cells; 2019 Jul; 8(7):. PubMed ID: 31323891
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
    Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
    Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
    Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
    PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
    Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
    Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
    [TBL] [Abstract][Full Text] [Related]  

  • 87. MiR-153 inhibits the resistance of lung cancer to gefitinib via modulating expression of ABCE1.
    Wang L; Lv X; Fu X; Su L; Yang T; Xu P
    Cancer Biomark; 2019; 25(4):361-369. PubMed ID: 31306106
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
    Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
    Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
    Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor knockout mice.
    Calpe-Berdiel L; Zhao Y; de Graauw M; Ye D; van Santbrink PJ; Mommaas AM; Foks A; Bot M; Meurs I; Kuiper J; Mack JT; Van Eck M; Tew KD; van Berkel TJ
    Atherosclerosis; 2012 Aug; 223(2):332-41. PubMed ID: 22748276
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies.
    Mack JT; Brown CB; Garrett TE; Uys JD; Townsend DM; Tew KD
    Biomed Pharmacother; 2012 Sep; 66(6):403-8. PubMed ID: 22898081
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
    Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
    Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
    Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
    Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
    Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
    Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The ATP-binding cassette transporter-2 (ABCA2) regulates cholesterol homeostasis and low-density lipoprotein receptor metabolism in N2a neuroblastoma cells.
    Davis W
    Biochim Biophys Acta; 2011 Dec; 1811(12):1152-64. PubMed ID: 21810484
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
    Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
    Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
    [TBL] [Abstract][Full Text] [Related]  

  • 98. miR-1/133a and miR-206/133b clusters overcome HGF induced gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations.
    Jiao D; Jiang C; Zhu L; Zheng J; Liu X; Liu X; Chen J; Tang X; Chen Q
    J Drug Target; 2021 Dec; 29(10):1111-1117. PubMed ID: 33955799
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Quantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4.
    Tsukamoto M; Sato S; Satake K; Miyake M; Nakagawa H
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28677646
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    Pao W; Miller VA; Politi KA; Riely GJ; Somwar R; Zakowski MF; Kris MG; Varmus H
    PLoS Med; 2005 Mar; 2(3):e73. PubMed ID: 15737014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.